DHL Group will invest €2 billion over the next five years to boost its life sciences and healthcare logistics business across the Americas, Asia Pacific and Europe/Middle East/Africa.
With the global healthcare logistics market set for strong growth in the coming years, DHL Health Logistics – the new consolidated brand for all DHL activities in this sector – aims to double its revenues from €5.6 billion in 2024 to over €10 billion by 2030.
This would bring the business, which will grow with the recently announced acquisition of US-based courier Cryopdp, closer to arch-rivals UPS and FedEx as well as leading 3PL players such as Kuehne & Nagel and DB Schenker which are all expanding their own activities in this sector.
Worldwide investments
DHL Group said the investment plan supports its Strategy 2030 and reinforces its commitment to helping healthcare customers grow, innovate, and serve patients more effectively worldwide.
With 50% of the investment allocated to the Americas, 25% to Asia Pacific, and 25% to the EMEA region, DHL is expanding its global footprint to deliver integrated, faster, more reliable, and patient-centric logistics solutions wherever healthcare companies operate.
Serving customer missions
